

Mercado Alternativo Bursátil Plaza de la Lealtad, 1 28014 Madrid

Granada, 16 March 2015

RELEVANT FACT OF NEURON BIO

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB the company, Neuron Bio, S.A., hereby puts in knowledge on 11 March 2015 that Neuron Bio has registered an application with the Spanish Patents and Trademarks Office (OEPM) for a new European patent.

This patent protects a tool that allows to diagnostic the Alzheimer's disease and to predict the disease in its most early stages improving so the efficacy of current diagnostic methods. The patented method by Neuron Bio is also minimally invasive as it only requires a blood sample analysis, instead of the current biomarkers analysis of cerebrospinal fluid used in the clinical diagnosis of the disease.

The tool may be of great value for the pharma industry that develops compounds for the Alzheimer's disease in clinical stages because it will permit the identification of suitable individuals to participate in such assays, as well as the effects evaluation of drugs in the course of the disease. This tool will also enable the design of early diagnosis systems for the Alzheimer's disease.

Considering the relevance of this scientific advance, the board of directors will evaluate the different options and business strategies that this tool offers to the company and will inform regularly the market about the taken decisions and if applicable submitting them to its shareholders.

Press release is enclosed.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate Chairman of the Board of Directors



Press release

NEURON BIO DEVELOPS A NEW DIAGNOSTIC METHOD FOR THE ALZHEIMER'S DISEASE

- The new patented method consists of identifying a range of biomarkers from blood samples.
- It improves significantly current measurement techniques of cerebrospinal fluid and avoids more complex and invasive techniques.

Granada 16 March 2015. **Neuron Bio (NEU.MC)** has registered a patent for the diagnosis of the Alzheimer's disease that is expected to be an important advance against this disorder because it is a non-invasive method for the patient and it is also quick and simple done by a blood test.

The new method, based on the identification of a range of biomarkers allows to diagnose in a reliable way Alzheimer's patients and also to anticipate the progress of the disease before clinical symptoms such as dementia appear, thus improving the efficacy of current methods (see graph). The patent achieves better results than similar tools in development by reference research centers (Stanford University, King's College, Rochester University or the The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) (see table).

This new patent application has been possible thanks to researchers of the Neuron Bio team and the active participation of researchers from Spanish reference hospitals such as Virgen de las Nieves and Clínico of Granada, Ramón y Cajal and La Paz of Madrid. In words of the president of Neuron Bio, Dr. Fernando Valdivieso, "it is one of the major milestones of the company regarding the work we have carried out during the last 10 years related to prevention, diagnosis and treatment of the Alzheimer's disease. This is a clear progress in regard to current methods and ads to the diagnosis patent portfolio of the company, which uses biomarkers for the diagnostic of neurodegenerative diseases."

The new method will facilitate clinical diagnoses of dementia due to the alternative it offers by using a blood sample instead of the current analysis of cerebrospinal fluid that brings the patient to an uncomfortable lumbar puncture and to longer analysis and evaluation processes.

Dr. Javier S. Burgos, CEO of Neuron Bio, stated "this tool will not only be useful for clinical practice, but it also will be of great value for big pharma companies that have compounds for the Alzheimer's disease in clinical stages. It will allow the identification of suitable individuals to participate in assays, reducing





costs and evaluating their effects on the disease course, thus increasing so success possibilities of new treatments."


The project, in which scientists and researchers of Neuron Bio have been working the last 3 years, is supported by the Technology Corporation of Andalusia CTA and financed by the regional Department of Economy, Innovation, Science and Employment of Andalusia and by the Ministry of Economy and Competitiveness of the Spanish Government.

More information: https://www.youtube.com/watch?v=hNayJXK7FqM





Graph



Diagnostic capacity for AD by biomarkers in Cerebrospinal fluid (CSF)

¹Is considered a diagnostic method to have good capacity for discrimination when the area under the ROC curve is above 0.7. ²Craig-Schapiro R. et al. PLoS One. (2011). Washington University School of Medicine. St. Louis. Missouri. USA.

³Pattent application Neuron Bio (2015), SPAIN.

Table

Study	Country	Sample size	# Biomarkers	Diagnostic capacity [*]
Stanford University ¹	USA	83	18	0,80
Rochester University NY ²	USA	106	10	0,83
King's College of London ³	United Kingdom	220	10	0,84
AIBL ⁴	Australia	961	8	0,87
Neuron Bio TOOL	SPAIN	311	5	0,88

The best results are indicated in red/ *Area Under Curve ROC / ¹Ray S. et al. Nature Medicine 2007. ²Mapstone M. et al. Nature Medicine 2014. ³Hye A. et al. Alzhiemer's & Dementia 2014. ⁴Doecke J.D. et al. Archives of Neurology 2012.

For further information:

Malena Valdivieso mvaldivieso@neuronbio.com Tef.: +34 958 750 598 www.neuronbio.com





NOTE FOR EDITORS

About Neuron Bio

Neuron Bio develops and manages biosolutions and projects in the biotechnological field for their application in the pharmaceutical and oleochemical industry through its subsidiaries and its specialized areas.

Its **pharma division** is mainly devoted to the search of drugs for the prevention and treatment of neurodegenerative diseases, particularly for the Alzheimer's disease.

Its **diagnostic division** develops tools and biomarkers for the diagnosis of human diseases, principally for those of the Central Nervous System as in the case of the Alzheimer's disease.

Its **service division** develops research projects as well as consultancy services for public institutions and for companies of the pharmaceutical, biotechnological, agro-food and animal health area.

Neuron Bio owns a broad and diverse high value molecule collection, neuroprotective compounds, 9 patent applications (2 of them recently granted by the European Union and other 1 also granted recently by the US Patent and Trademark Office) and exclusive platforms for drug discovery and development.

Neol Bio, a 100% subsidiary of Neuron Bio is devoted to the development of innovative processes within the microbial industrial biotechnology for its application in oleochemical, bioenergy and biopolymer sectors.

It has a highly qualified team of researchers with wide experience in R&D and renowned prestige in the sector, who participate actively in numerous scientific projects.

Neuron Bio has facilities in Granada and Madrid that are connected with university research centers and is quoted on the Alternative Stock Market (MAB) in Spain.

